Sinopharm (Beijing): BBIBP-CorV

mankhwala

Sinopharm (Beijing): BBIBP-CorV

Kufotokozera Kwachidule:

Sinopharm BBIBP-CorV COVID-19 ndi katemera wosagwira ntchito wopangidwa ndi tizilomboto tomwe timakula chifukwa cha chikhalidwe chomwe sichikhala ndi mphamvu yotengera tizilombo. Woyimira katemerayu adapangidwa ndi Sinopharm Holdings ndi Beijing Institute of Biological Products.


Mankhwala Mwatsatanetsatane

Zogulitsa

Gawo 1

1 Kuyesedwa

CHICR2000032459

China

GAWO 2

2 Mayesero

NCT04962906

Argentina

CHICR2000032459

China

GAWO 3

6 Ziyeso

NCT04984408

CHICR2000034780

United Arab Emirates

NCT04612972

Peru

NCT04510207

Bahrain, Egypt, Jordan, United Arab Emirates

NCT04560881, BIBP2020003AR

Argentina

NCT04917523

United Arab Emirates

Kuvomerezeka

Mndandanda Wogwiritsa Ntchito Mwadzidzidzi wa WHO 59 Mayiko

Angola 、 Argentina 、 Bahrain 、 Bangladesh 、 Belarus 、 Belize 、 Bolivia (Plurinational State of) 、 Brazil 、 Brunei Darussalam 、 Cambodia 、 Cameroon 、 Chad 、 China 、 Comoros 、 Egypt 、 Equatorial Guinea 、 Gabon 、 Gambia 、 Georgia 、 Guyana 、 Hungary 、 ndonesia 、 Iran (Republic of Islamic) 、 Iraq 、 Jordan 、 Kyrgyzstan Republic Anthu a Democratic Republic of Lao

Lebanon 、 Malaysia 、 Maldives 、 Mauritania ur auritius 、 Mongolia 、 Montenegro 、 Morocco 、 Mozambique 、 Namibia 、 Nepal 、 Niger 、 North Macedonia 、 Pakistan 、 Paraguay 、 Peru 、 Philippines 、 Republic of the Congo 、 enegal 、 Serbia 、 Seychelles 、 Sierra Leone 、 Solomon 、 Islands 、 Somalia 、 Sri Lanka 、 Thailand 、 Trinidad ndi Tobago 、 Tunisia 、 United Arab Emirates 、 Venezuela (Bolivarian Republic of) 、 Viet Nam 、 Zimbabwe

Sinopharm BBIBP-CorV COVID-19 ndi katemera wosagwira ntchito wopangidwa ndi tizilomboto tomwe timakula chifukwa cha chikhalidwe chomwe sichikhala ndi mphamvu yotengera tizilombo. Woyimira katemerayu adapangidwa ndi Sinopharm Holdings ndi Beijing Institute of Biological Products.

Katemera wa Sinopharm BBIBP-CorV amagwira ntchito polola chitetezo chamthupi kutulutsa ma antibodies olimbana ndi SARS-CoV-2 beta coronavirus. Katemera wosagwira ntchito wa virus akhala akugwiritsidwa ntchito kwazaka zambiri, monga katemera wa chiwewe ndi katemera wa hepatitis A. Ukadaulo uwu wagwiritsidwa ntchito bwino ku katemera wodziwika bwino, monga katemera wa chiwewe.

Matenda a Sinopharm a SARS-CoV-2 (WIV04 strain ndi nambala ya library MN996528) adasiyanitsidwa ndi wodwala ku Jinyintan Hospital ku Wuhan, China. Tizilomboti timafalikira pachikhalidwe mumayendedwe amtundu wa Vero, ndipo supernatant yamaselo omwe anali ndi kachilomboka sanayendetsedwe ndi β-propiolactone (1: 4000 vol / vol, 2 mpaka 8 ° C) kwa maola 48. Pambuyo pofotokozera za zinyalala zamaselo ndikuwonjezera mphamvu, kuyimitsidwa kwachiwiri kwa β-propiolactone kunachitika m'mikhalidwe yofanana ndi yoyamba kusatsegula. Malinga ndi WHO, katemerayu adayikidwanso pa 0,5 mg ya alum ndikuyiyika m'mitsempha yoyikidwiratu mu 0,5 mL yamchere wosabala wa phosphate wopanda zotetezera.

Pa Disembala 31, 2020, State Drug Administration yalengeza kuvomereza kwa katemera woyeserera wopangidwa ndi Sinopharm.

Pa Meyi 7, 2021, World Health Organisation yalengeza kuvomereza kwa katemerayu. Mndandanda wazogwiritsira ntchito mwadzidzidzi wa WHO udathandizira mayiko kuti afulumizitse zilolezo zawo zolembetsa ndi kupereka katemera wa COVID-19. Gulu la Katswiri Woyang'anira za Katemera ku WHO lakwanitsanso kuwunika katemerayu. Kutengera maumboni onse omwe alipo, WHO imalimbikitsa katemera wa mitundu iwiri, patadutsa milungu itatu kapena inayi, kwa akulu azaka 18 kapena kupitilira apo. Mphamvu ya katemera motsutsana ndi matenda am'magazi komanso opezeka mchipatala akuti ndi 79% ya mibadwo yonse kuphatikiza.

American Medical Association idasindikiza "Randomized Clinical Trial: Zotsatira za Katemera Wachiwiri wa SARS-CoV-2 pa Syndromeomatic COVID-19 Infection in Adult" pa Meyi 26, 2021, pomaliza kuti "pakuwunikiraku kwakanthawi koyeserera kwachipatala, Achikulire 2 katemera wothandizidwa ndi SARS-CoV-2 omwe amaperekedwa pakuwunika kwakanthawi kwakanthawi kwamayesero azachipatala adachepetsa kwambiri chiopsezo cha COVID-19, ndipo zovuta zoyipa sizinali zachilendo. " Mchigawochi 3 kuyesedwa kosasinthika kwa achikulire, mphamvu ya katemera wothandizira ma virus omwe ali ndi kachilombo koyambitsa matenda a COVID-19 anali 72.8% ndi 78.1%, motsatana. Katemera wa 2 anali ndi zovuta zoyipa zomwe zimachitika pafupipafupi mofanana ndi gulu lolamulira la alum okha, ndipo ambiri anali osagwirizana ndi katemera. Kufufuza kofufuza kunapeza kuti katemera 2 adayambitsa ma antibodies oyerekeza, ofanana ndi zotsatira za kuyesa kwa gawo la 1/2.

Bungwe la WHO SAGE Working Group lidasindikiza ndemanga ya katemera wa Sinopharm / BBIBP COVID-19 pa Meyi 10, 2021. Katemera wa GAVID-19 wa GAVI amaphatikiza chowunikira cha katemera chomwe chimauza ogwira ntchito zaumoyo ngati katemerayu wasungidwa bwino ndipo sanapezeke kutentha kwambiri. Zotsatira zake, kuwonongeka, GAVI idanenanso pa Meyi 14, 2021. ma labels anzeru opangidwa ndi Zebra Technologies ndikupangidwa ndi Temptime Corporation, amakhala ndi bwalo lokhala ndi malo owala owala pakati, opangidwa ndi mankhwala opanda mtundu omwe amasintha mtundu mosasinthika pakapita nthawi. . Izi zimakhala zakuda kwambiri kuti ziwonetse kuwonetserako kutentha kowonjezera. Mbaleyo ikakhala kuti yatenthedwa mopitilira momwe imasungidwira, malowo amakhala amdima kuposa bwalolo, kuwonetsa kuti katemerayu sayenera kugwiritsidwanso ntchito.

Nambala yolembetsera katemera wa National Drug BBIBP-CorV COVID-19: DB15807.


  • Previous: Zamgululi
  • Ena:

  • Lembani uthenga wanu apa ndi kutumiza kwa ife